Addressing the potential toxicities of the non-specific P-glycoprotein modulation by amalgamation with targeted approach in MDR tumors

Medical Hypotheses

Volumn 82, Issue 2, 2014, Pages 240-242

  Negi, Lalit Mohan ^a   Jaggi, Manu ^a   Talegaonkar, Sushama ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CAMPTOTHECIN DERIVATIVE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; IMATINIB; IRINOTECAN; MITOMYCIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PACLITAXEL; TENIPOSIDE; TOPOTECAN; TRIMETREXATE; VINBLASTINE; VINCRISTINE; VINDESINE; XENOBIOTIC AGENT;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG ACCUMULATION; EFFUSION; HUMAN; HYPOTHESIS; INTESTINE ABSORPTION; MODULATION; MULTIDRUG RESISTANCE; PROTEIN FUNCTION; TUMOR RESISTANCE;

DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; MODELS, THEORETICAL; NANOPARTICLES; P-GLYCOPROTEIN; XENOBIOTICS;

EID: 84892365246     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.12.006     Document Type: Article

References (26)

1. Dean M., Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr 2001, 33:475-479.
2. Ambudkar S.V., Dey S., Hrycyna C.A., Ranmachandra M., Pastan I., Gottesman M.M. Biochemical, cellular and pharma-cological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361-398.
3. Silverman J.A. Membrane transporters as drug targets, multidrug-resistance transporters 1999, vol. 12:353-386. Kluwer Academic /Plenum Publishers, New York.
4. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000, 11:265-283.
5. German U.A. P-glycoprotein - a mediator of multidrug resistance in tumor cells. Eur J Cancer 1996, 33A:927-944.
6. Aungst B.J. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev 1999, 39:105-116.
7. Suzuki H., Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 2000, 12:3-12.
8. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in-vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41:1967-1972.
9. Fischer V., Rodríguez-Gascón A., Heitz F., Tynes R., Hauck C., Cohen D., et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 1998, 26:802-811.
10. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53:4595-4602.
11. Dantzig A.H., Alwis D.P., Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Del Rev 2003, 55:133-150.
12. Soma C.E., Dubernet C., Bentolila D., Benita S., Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000, 21:1-7.
13. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new Polymer-Lipid Hybrid Nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Rel 2006, 116:275-284.
14. Bansal T., Akhtar N., Iqbal Z., Ahmed F.J., Jaggi M., Khar R.K., et al. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009, 14:1067-1074.
15. Hubensack M., Muller C., Hocherl P., Fellner S., Spruss T., Bernhardt G., et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 2008, 134:597-607.
16. Patil Y., Sadhukha T., Ma L., Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Rel 2009, 136:21-29.
17. Hugger E.D., Audus K.L., Borchardt R.T. Effects of poly (ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci 2002, 91:1980-1990.
18. Choi S., Jo B.W. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm 2004, 280:221-722.
19. Varma M.V., Panchagnula R. Enhanced oral Paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005, 25:445-453.
20. Shono Y., Nishihara H., Matsuda Y., Furukawa S., Okada N., Fujita T., et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci 2004, 93:877-885.
21. Batrakova E.V., Li S., Brynskikh A.M., Sharma A.K., Li Y., Boska M., et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release 2010, 143:290-301.
22. Emanuel K.A. An air-sea interaction theory for tropical cyclones. Part I: steady-state maintenance. J Atmos Sci 1986, 43:585-605.
23. Werle M., Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release 2006, 10:41-46.
24. Horton J.K., Thimmaiah K.N., Houghton J.A., Horowitz M.E., Houghton P.J. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 1989, 38:1727.
25. Sridhar R., Dwivedi C., Anderson J., Baker P.B., Sharma H.M., Desai P., et al. Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst 1992, 84:1653.
26. Bertrand Y., Capdeville R., Balduck N., Philippe N. Cyclosporin A used to reverse drug resistance increases vincristine neurotoxicity. Am J Hematol 1992, 40:158.